Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Addiction Medicine
Vaccine to treat nicotine addiction earns proof of efficacy in phase 2 trial
June 17th, 2005
Cytos Biotechnology AG announced that its vaccine candidate CYT002-NicQb to treat nicotine addiction has achieved proof of efficacy. The phase 2 clinical trial results were presented by Dr. Jacques Cornuz (CHUV Lausanne), principal investigator, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, on behalf of the 3 Swiss study centers. The study included 341 smokers and assessed safety, tolerability and efficacy of the vaccine candidate. Efficacy of the vaccine was determined by continuous abstinence from smoking between week 8 and 24 after treatment start and was measured by self-reporting of the...
Source: Drug Week (2005-06-17)
|
